CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Non-Hodgkins Lymphoma

NCT04089215 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

82

Enrollment

INDUSTRY

Sponsor class

Conditions

Lymphoma, Non-Hodgkin
Diffuse Large B Cell Lymphoma
Follicular Lymphoma

Interventions

BIOLOGICAL: CD19-targeted Chimeric Antigen Receptor (CAR) T Cells

Sponsor

Shanghai Ming Ju Biotechnology Co., Ltd.